Seres Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Seres Therapeutics, Inc. (MCRB) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $0 as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-05
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $0.00.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $144.00K.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $228.00K.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $2.29M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $144.00K 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $228.00K 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $2.29M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $87.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | $245.00K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $0.00 10-K · filed 2025-03-13 | |
| 2023-09-30 | $135.00K 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $6.83M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $12.19M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $11.61M 8-K · filed 2024-08-15 | |
| 2022-09-30 | $16.41B 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $854.13M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $19.85B 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $28.01M 10-K · filed 2023-03-07 | $28.01B 10-K · filed 2022-03-01 |
| 2021-09-30 | $19.88B 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $143.22M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $122.10M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $156.63M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $196.03M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $10.14M 10-Q · filed 2020-07-28 | |
| 2020-03-31 | $4.05M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $3.43M 10-K · filed 2021-03-02 | |
| 2019-09-30 | $4.23M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $3.19M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $9.68M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $4.96M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $9.36B 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $11.51M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $9.99M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $15.81M 10-K · filed 2019-03-06 | |
| 2017-09-30 | $36.79M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $20.88M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $21.14M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $16.74M 10-K · filed 2018-03-08 | |
| 2016-09-30 | $21.89M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $88.44M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $93.31M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $136.94M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $111.83M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $168.92M 10-Q · filed 2015-08-10 | |
| 2014-12-31 | $59.50M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |